Substance and claimed effects

Topical sunscreen is a leave-on skin product containing one or more UV-filtering actives — either organic ("chemical") molecules such as avobenzone, octinoxate, octocrylene, homosalate, oxybenzone, octisalate, and (outside the US) ecamsule and Tinosorb S/M; or inorganic ("mineral") particulates of zinc oxide and titanium dioxide. The labelled SPF rates erythemal (UVB-dominant) protection in a standardised in-vivo test at 2 mg/cm²; a broad-spectrum claim additionally requires UVA protection meeting either the FDA critical-wavelength test (≥370 nm) or the EU UVA-PF ≥ SPF/3 ratio Lim et al. 2017. Claims this entry treats as in-scope: prevention of sunburn (acute UVB damage), prevention of cutaneous squamous-cell carcinoma (SCC), basal-cell carcinoma (BCC), and cutaneous melanoma; reduction of photoaging (wrinkles, mottled pigmentation, solar elastosis, telangiectasias); and reduction of UV-induced facial hyperpigmentation including melasma and post-inflammatory pigmentation, with a partial role for tinted/iron-oxide formulations in visible-light protection Lyons et al. 2021. Vitamin-D synthesis impact is in-scope as a counter-claim. Out of scope: oral photoprotection (Polypodium leucotomos, nicotinamide), antioxidant serums, UPF clothing, sun-avoidance behaviour, retinoids, and laser/IPL — each addressed in their own entry or category.

Evidence by addressing question

Mechanism

UVB (290–320 nm) is absorbed directly by DNA bases, generating cyclobutane pyrimidine dimers and 6-4 photoproducts. Mis-repair of these lesions drives the characteristic C→T and CC→TT "UV signature" mutations seen in TP53, CDKN2A, NOTCH1, and PTCH1 across SCC, BCC, and melanoma D'Orazio et al. 2013. UVA (320–400 nm) penetrates deeper (into the reticular dermis), generates reactive oxygen species that produce 8-oxoguanine lesions and lipid peroxidation, and induces matrix metalloproteinases (notably MMP-1) that cleave dermal collagen — the mechanism most directly tied to photoaging Krutmann et al. 2017. UVA also drives immediate pigment darkening (oxidation of preformed melanin) and persistent pigmentation; UVB drives delayed tanning (melanogenesis). Both wavebands suppress cutaneous adaptive immunity via DNA damage in Langerhans cells. Sunscreens work by absorbing (organic filters), reflecting, or scattering (mineral filters) incident UV before it reaches viable keratinocytes and dermal fibroblasts; modern broad-spectrum formulations integrate multiple filters to cover the full 290–400 nm range and, with iron-oxide tints, partial coverage into the 400–500 nm visible spectrum Lyons et al. 2021. SPF is logarithmic-leaning: SPF 15 blocks ~93% of erythemal UVB, SPF 30 ~97%, SPF 50 ~98% — but this is at the testing dose of 2 mg/cm², which almost no real user reaches (see Protocol).

Evidence

The strongest sunscreen evidence is the Nambour Skin Cancer Prevention Trial — a randomised controlled trial of 1,621 adults in subtropical Queensland (mean age 49 at entry, predominantly fair-skinned) assigned to either daily SPF 16 sunscreen to head, neck, arms, and hands or to discretionary sunscreen use, with parallel betacarotene/placebo arms. After 4.5 years (1992–1996), the daily-use arm had a 39% reduction in SCC tumour counts (rate ratio 0.61, 95% CI 0.46–0.81) and a non-significant reduction in BCC tumour counts; no difference in person-based incidence of either tumour at that timepoint Green et al. 1999. The follow-up at 8 years post-trial-end showed sustained SCC reduction (rate ratio 0.62, 95% CI 0.38–0.99) van der Pols et al. 2006. The 10-year melanoma follow-up was the headline result: the daily-sunscreen arm had 11 primary melanomas versus 22 in the control arm (HR 0.50, 95% CI 0.24–1.02 for any melanoma; HR 0.27 for invasive melanoma, 95% CI 0.08–0.97) — the first randomised demonstration that sunscreen reduces melanoma incidence in humans Green et al. 2011.

The Hughes 2013 sub-study of the same cohort assessed photoaging blinded by silicone skin-cast micrography of the back of the hand at baseline and at 4.5 years. The daily-sunscreen arm showed no detectable increase in photoaging on a 6-point scale; the discretionary arm progressed by 24% (OR for greater photoaging in discretionary 1.24, 95% CI 1.07–1.43, p = 0.004) Hughes et al. 2013. This is the only randomised, blinded, gross-morphology evidence that daily sunscreen prevents visible aging — and it was achieved with SPF 16 in a population already 40+ at enrolment.

Observational evidence is broadly consistent. The 2015 Australian attributable-fraction analysis estimated that regular sunscreen use prevented approximately 14% of melanomas and a larger share of keratinocyte cancers in the Australian population, with the analysis grounded in the Nambour effect sizes projected onto national exposure data Olsen et al. 2015. Population-level Australian melanoma incidence in birth cohorts born after the 1980s SunSmart campaign has flattened and begun to decline at younger ages, consistent with a real prevention effect at scale Whiteman et al. 2016. The USPSTF 2018 recommendation gave behavioural counselling on sun protection (including sunscreen) a B grade for fair-skinned individuals aged 6 months to 24 years and a C grade for adults over 24, reflecting the strength of evidence rather than skepticism about the intervention USPSTF 2018.

Protocol

The label SPF is achieved at 2 mg/cm² — roughly a heaped teaspoon (~5 ml) for the face and neck alone, and approximately 30 ml (a shot glass) for whole-body coverage in a swimsuit. Real-world application is consistently 0.5–1.0 mg/cm², or 25–50% of the testing dose, across studies of beachgoers, ski-slope users, and instructed clinical-trial participants Petersen & Wulf 2014. Because SPF protection falls non-linearly with applied dose (approximately SPF^applied/test), an SPF 50 product applied at half-dose delivers roughly the protection of SPF 7. The pragmatic compensations are: (a) choose SPF 30+ to absorb the headroom users will lose to under-application, and (b) reapply every 2 hours during continuous exposure and after swimming or heavy sweating, both because filters are physically removed/displaced and because the time-integrated dose to skin compounds with sun-hours Diffey 2001.

The American Academy of Dermatology and most national bodies converge on the same three-criterion product spec: broad-spectrum, SPF 30 or higher, water-resistant for outdoor/sweat use AAD 2024. Daily face-and-neck use is recommended year-round in any latitude with non-trivial daytime sun exposure; for incidental urban exposure most days, a single morning application without reapplication captures most of the available benefit because cumulative dose is small. For deliberate sun exposure (beach, hike, ski), the 2-hour reapplication interval and the full 2 mg/cm² target both matter. Optimal-application protocols can permit functional vitamin-D synthesis even on a high-UV holiday: Young et al. randomised UK participants to a one-week Tenerife trip with SPF 15 applied to the European standard 2 mg/cm²; 25(OH)D rose by a median ~28 nmol/L without sunburn, indicating the under-application that limits photoprotection also leaves enough UVB through for cutaneous vitamin D synthesis Young et al. 2019.

Misconceptions

Several beliefs persist against the evidence. (1) "Dark skin doesn't need sunscreen." Skin cancer incidence is lower in Fitzpatrick V–VI skin but melanoma, when it occurs, is diagnosed at later stages with worse mortality (acral lentiginous in particular); UV-driven hyperpigmentation, melasma, and post-inflammatory pigmentation are major concerns and respond to daily broad-spectrum sunscreen, with tinted iron-oxide formulations adding visible-light protection that uncoloured products lack Lyons et al. 2021. (2) "Higher SPF is overkill." Given the under-application reality, SPF 30 is the practical floor, and SPF 50+ provides meaningful real-world headroom rather than redundant labelling Petersen & Wulf 2014. (3) "Sunscreen causes skin cancer / blocks vitamin D / is endocrine-disrupting." See Credibility range; the human data on cancer outcomes is unidirectional (sunscreen reduces, not increases), and the Young 2019 trial directly showed vitamin D rose despite SPF 15 use Young et al. 2019. (4) "Cloudy days don't need sunscreen." Cloud cover transmits roughly 80% of UVA and 50–80% of UVB depending on density; daily-use protocols don't depend on perceived sunshine.

Failure modes

The dominant failure is under-application at the labelled dose; the secondary failure is missed real estate — ears, lips, the rim of the scalp where hair parts, the dorsum of the feet, the back of the neck in short-hair users, and the upper eyelid where most users skip out of stinging-eye concern. Reapplication is forgotten or skipped after sweating/swimming, which compounds with the application-dose problem. Expired or heat-degraded product (left in cars, beach bags) loses filter efficacy; the FDA expiry date assumes ambient storage. Sunscreen as the only photoprotection — without hat, sunglasses, UPF clothing, or shade — caps achievable protection well below what combined behaviours deliver; the Nambour effect sizes are for sunscreen on top of a normal Queensland sun-protection culture, not as a substitute for it Green et al. 2011.

Contraindications

Two real ones. Infants under 6 months: FDA and AAD recommend sun avoidance and protective clothing rather than topical sunscreen; transcutaneous absorption is higher in infant skin and the limited skin surface area required for sun protection is more efficiently handled by clothing and shade. Documented contact allergy to a specific filter (most commonly oxybenzone/benzophenone-3, sometimes octocrylene, occasionally avobenzone) — switch to a mineral-only product. Practical considerations rather than contraindications: pregnancy and breastfeeding — chemical filters reach plasma above the FDA 0.5 ng/mL threshold for required toxicology under the 2019/2020 maximal-use studies Matta et al. 2019 Matta et al. 2020, but no human or animal harm has been demonstrated at biologically plausible exposures; the conservative default for those who prefer caution is mineral-only formulations during pregnancy. Acne-prone skin: filter and vehicle choice (non-comedogenic, fluid, fragrance-free) matters more than chemical-vs-mineral.

Audience

Effect generalises broadly. The Nambour trial population was Fitzpatrick I–III, mean age 49, in latitude 26°S (high ambient UV). Effect sizes for melanoma and SCC prevention are largest in fair-skinned individuals with high baseline exposure; the absolute (not relative) benefit shrinks in lower-UV latitudes and darker skin, but does not vanish — photoaging, hyperpigmentation, and the long-tail melanoma reduction still apply. Children: USPSTF B-grade counselling recommendation for ages 6 months to 24 years reflects the importance of cumulative exposure that begins in childhood USPSTF 2018. Outdoor occupational workers (construction, agriculture, lifeguards): substantially higher SCC and melanoma incidence; daily sunscreen plus UPF clothing is standard occupational guidance. Skin of colour: lower skin cancer absolute risk but real photoaging and pigmentation benefit; tinted formulations expand spectrum coverage into the visible range relevant to melasma Lyons et al. 2021.

Alternatives

Photoprotection is a stack, not a single intervention. Behavioural: sun avoidance during peak UV-index hours (10am–4pm in most temperate latitudes), seeking shade, wearing wide-brimmed hats, long sleeves, sunglasses, and UPF-rated clothing. Behavioural avoidance is more effective per unit effort than sunscreen for prolonged outdoor exposure; sunscreen earns its place because most modern lives include face/hand exposure during incidental outdoor time when clothing isn't worn. Oral photoprotection (Polypodium leucotomos extract, nicotinamide) has small-to-moderate effect sizes and is adjunctive — not a sunscreen replacement. Window film and car-cabin tint reduce in-vehicle UVA exposure (a real source of unilateral photoaging in long commutes). For deliberate UV exposure for vitamin D, brief mid-day exposure of arms and legs (5–15 minutes depending on skin type and latitude) is sufficient without burning, and is preferable to extended unprotected exposure.

Practicalities

Cost ranges from $8 drugstore tubes (Cetaphil, CeraVe, Neutrogena, EltaMD economy lines) to $50+ Japanese/Korean/French speciality formulations (Anessa, Beauty of Joseon, La Roche-Posay Anthelios). Daily face-and-neck use consumes approximately 30–60 ml/month; a daily user spends $30–$200/year. Vehicle and aesthetics drive adherence more than active-ingredient choice — a product the user dislikes is one they don't apply. Tinted mineral formulations cover blue-light/visible-light wavelengths uncoloured products miss Lyons et al. 2021 and double as makeup base. Sticks for ears, lips, around the eyes; sprays are convenient but lose dose to wind and routinely under-cover; lotions and creams remain the gold standard for measurable application. Storage: keep out of cars and beach bags in direct sun once opened; product oxidises faster at heat.

Stakes

Two timescales matter. Within years: visible photoaging on chronically exposed sites — periorbital wrinkles, perioral wrinkles, mottled hyperpigmentation, telangiectasias on the cheeks and nose, leathery thickening on the dorsum of the hands and the back of the neck. Cohort and twin studies attribute 80%+ of visible skin aging on chronically exposed sites to UV exposure rather than chronologic time Flament et al. 2013 Krutmann et al. 2017. Within decades: cumulative actinic damage manifests as actinic keratoses (rough scaly precancerous lesions), then keratinocyte cancers (BCC and SCC) requiring excision and leaving facial scars, and (for fair-skinned populations at high latitude or any-skinned populations at low latitude) melanoma, with a population-wide incidence projected to keep rising into the 2030s in fair-skinned populations Whiteman et al. 2016. Australian women born in the 1950s have ~1-in-7 lifetime BCC risk and ~1-in-20 melanoma risk by current cohort projections; the analogous US and northern European figures are lower but trending up.

Payoff

The Hughes 2013 trial offers the cleanest answer: 4.5 years of daily SPF 16 in a sun-exposed Queensland population produced measurably less photoaging on the back of the hand than discretionary use — a 24% reduction in visible-aging progression on a blinded silicone-cast scoring scale Hughes et al. 2013. Projected over decades, the longitudinal divergence is large: skin chronically protected from UV ages closer to the rate of unexposed buttock/inner-upper-arm skin, which is the "intrinsic aging" floor and is substantially slower than the photoaged baseline Flament et al. 2013. On the cancer-prevention side, daily users avoid the actinic-keratosis-to-keratinocyte-carcinoma trajectory at roughly the rate ratios observed in Nambour (~40% SCC reduction sustained at 8 years), and avoid 1-in-2-odds melanoma at the (small but real) Nambour effect size Green et al. 2011. Adherence is the modifier: payoffs scale with consistency, not with one-off application.

Out of scope

Adjacent topics this entry will signpost: oral antioxidant photoprotection (Polypodium leucotomos, nicotinamide), sun avoidance and shade behaviour, retinoid-based photoaging treatment, antioxidant serums (vitamin C/E/ferulic acid), and vitamin D supplementation as a hedge against any UV-avoidance shortfall. None of these substitute for sunscreen; the entry points readers at them as the rest of the photoprotection / anti-aging stack.

The credibility range

Optimist case

The Nambour trial is the gold-standard human evidence: a multi-decade randomised trial with hard endpoints (histology-confirmed skin cancers, blinded photoaging scoring), executed in a high-UV latitude with a population at meaningful baseline risk. It demonstrated SCC prevention, melanoma reduction, and photoaging prevention from a single intervention — SPF 16, daily, head and arms only — that nothing else in dermatology has matched. The effect sizes are clinically large (40% SCC reduction, 50% melanoma reduction, 24% less photoaging) and align with mechanism (UV → DNA damage → mutation → cancer, and UV → MMP induction → dermal collagen loss → wrinkles). Population-level data from Australia is consistent with the effect sizes scaling. Modern broad-spectrum SPF 30+ products are higher-protection than the SPF 16 of Nambour, so the contemporary intervention should be at least as effective. The safety record is extensive: half a century of widespread use, no demonstrated human harm at biologically relevant exposures, and the FDA absorption findings are a regulatory call for more data, not evidence of harm Matta et al. 2019. Vitamin D is a non-issue in real use — under-application leaves the UVB transmission window open for cutaneous synthesis, as directly demonstrated Young et al. 2019. Daily sunscreen is the single highest-leverage daily intervention in dermatology.

Skeptic case

The randomised melanoma evidence is one trial, in one geography, with confidence intervals (0.24–1.02 for any melanoma) that brush statistical insignificance. Most cohort observational studies show null or inverse associations between sunscreen use and melanoma — driven by confounding (sunscreen users self-select for higher exposure, fairer skin, and outdoor activities) but persistent enough that the synthesis isn't clean. The "sunscreen prevents melanoma" claim leans heavily on Nambour and on biological plausibility. UVA-vs-UVB filter balance in early decades of sunscreen use (UVB-only protection encouraging longer exposure with continued UVA dose) may have contributed to mixed observational findings — relevant to modern broad-spectrum products' inferred superiority but also relevant to which historical effect sizes apply to today's products. The FDA 2019/2020 trials found six commonly used organic filters (avobenzone, oxybenzone, octocrylene, homosalate, octisalate, octinoxate) at plasma concentrations exceeding the 0.5 ng/mL threshold above which the FDA requires non-clinical toxicology data, and the agency has not yet ruled those filters GRASE (generally recognised as safe and effective) Matta et al. 2019 Matta et al. 2020. Oxybenzone is a weak estrogen-receptor agonist and progesterone-receptor antagonist in vitro; in-vivo human endocrine effects at consumer exposures are unproven but not zero-probability, and reproductive/developmental data is thin Krause et al. 2012. The pragmatic skeptic concedes daily sunscreen prevents photoaging and keratinocyte cancers but reserves judgement on the magnitude of the melanoma benefit and on the long-term safety of certain organic filters at lifetime dosing.

The author's call

Daily broad-spectrum SPF 30+ sunscreen on exposed skin is one of the highest-evidence, highest-leverage interventions in the catalogue for the beauty-cumulative and longevity dimensions and a meaningfully strong one for short-term beauty (sunburn prevention) and morbidity prevention (actinic damage, NMSCs). The Nambour evidence is the closest thing dermatology has to a definitive randomised demonstration that the intervention works for the outcomes claimed. The systemic absorption findings warrant ongoing FDA review but do not justify abandoning chemical filters at the population level given the demonstrated cancer- and aging-prevention benefit; readers concerned about absorption (pregnancy, very young children) can default to zinc/titanium mineral products and lose nothing material. Evidence: 5. Controversy: 2 — strong consensus on the core benefit, real but contained debate on chemical-filter safety and on the precise magnitude of melanoma reduction.

Stakeholder and incentive map

• Pro side. Dermatology societies (AAD, EADV), public-health bodies (Australian Cancer Council SunSmart program, US Skin Cancer Foundation), national task forces (USPSTF), and the cosmetic-skincare industry, which sells sunscreen as a high-margin daily-use product. Aesthetic dermatology clinics have a strong indirect incentive: sunscreen is the cheapest input into the photoaging-prevention ecosystem that supports the entire field.
• Skeptic / counter-incentive side. A small but vocal "sun-is-life" lifestyle community (popular in fringe biohacking circles) argues that ancestral sun exposure is necessary for hormonal and metabolic health and that sunscreen has been over-marketed. The Environmental Working Group annually rates organic filters poorly and has driven mineral-only consumer demand, sometimes ahead of regulatory consensus. Hawaii, Palau, and certain Caribbean jurisdictions have banned oxybenzone and octinoxate over coral-reef concerns — a real but separate question from human safety. Reef concerns have shifted the consumer market toward zinc/titanium mineral products and Tinosorb-class organics.
• Regulatory. The FDA's 2019 proposed rule re-opened the sunscreen monograph after decades; only zinc oxide and titanium dioxide are currently FDA-classified GRASE. The EU regulates filters under the Cosmetics Regulation and has approved a broader set of modern filters (Tinosorb S, Tinosorb M, Mexoryl SX/XL, bemotrizinol, bisoctrizole) that remain unavailable in the US, a regulatory gap dermatologists routinely flag.

Population variability

The Fitzpatrick scale matters less for "does sunscreen work" than for "how much absolute risk is on the table." Fitzpatrick I–II skin in temperate latitudes accumulates the largest absolute risk reduction for keratinocyte cancers and melanoma; daily face-and-neck sunscreen plus standard sun protection puts these readers in the lowest-risk bracket their skin allows. Fitzpatrick V–VI skin has lower absolute keratinocyte-cancer risk but real photoaging and pigmentation outcomes that respond to the same daily-use protocol; the addition of tinted (iron-oxide) formulations is most relevant to this group because melasma and post-inflammatory hyperpigmentation are partly driven by visible-light wavelengths that uncoloured sunscreens transmit Lyons et al. 2021. Outdoor occupational workers (construction, agriculture, fishing, lifeguarding) accumulate cumulative-exposure-driven SCC and BCC at rates that justify the highest-protection products plus UPF clothing — sunscreen alone is inadequate. Older adults already carrying actinic keratoses still benefit from daily sunscreen: the Nambour follow-up cohort included adults to age 69 at enrolment, and the photoaging arm started at mean age 49. Children: cumulative pre-18 exposure is a major lifetime-risk driver, especially for melanoma; the USPSTF B-grade recommendation for 6-months-to-24-years counselling reflects this. Pregnancy: no demonstrated harm from any approved filter at consumer exposures; mineral-only is a reasonable conservative default for those who prefer it. Vitamin-D status: the most commonly raised concern is empirically the least real — typical under-application leaves UVB transmission adequate for cutaneous synthesis even on vacation-level sun exposure Young et al. 2019.

Knowledge gaps

• Replication of the Nambour melanoma RCT result. No second randomised trial of similar design has been completed; replication in a different latitude/skin-type population would tighten the wide confidence intervals.
• Long-term safety of organic filters at plasma exposures above the FDA threshold. The 2019/2020 maximal-use studies established that absorption occurs; what's needed is the toxicology and population-cohort data that establishes (or rules out) clinical significance. Endocrine endpoints (reproductive, thyroid) are the most-flagged candidates Krause et al. 2012.
• Behavioural confounding in observational sunscreen-melanoma studies. Disentangling sunscreen-use from total UV dose remains methodologically difficult; sun-exposure diaries plus objective dosimetry would help.
• Visible-light photoprotection. Iron-oxide-containing tinted sunscreens demonstrably reduce visible-light-induced pigmentation in melasma; the population-level effect size and optimal formulation remain active research Lyons et al. 2021.
• Real-world adherence and dose interventions. Mechanisms to bridge the labelled-vs-applied dose gap — better dispensers, vehicle reformulation, tinted/cosmetic incentive products — are studied but not standardised.

Scope coverage versus the brief. Brief named SPF and broad-spectrum claims, application amount and reapplication cadence, sunburn, photoaging, and skin cancer risk. All four are covered end-to-end. Both chemical and mineral filter classes are introduced in mechanism with brand-name examples; the chemical-vs-mineral choice surfaces again in contraindications and practicalities where it's load-bearing for the reader, rather than as a stand-alone comparison section.

Hard scoping calls.

• Vitamin D as out-of-scope, not a callout. It's the most-raised concern in lay discussion and the dossier covers it, but Young 2019 settles it cleanly enough that the article handles it in the closing pointer rather than dedicating a misconceptions paragraph. The dossier carries the longer treatment.
• Coral-reef and oxybenzone bans. A genuine policy story (Hawaii, Palau) but a different question from human-safety or efficacy. Mentioned in the stakeholder map of the dossier; left out of the article to keep contraindications focused on the reader's own skin.
• Melasma as a sub-population concern. Touched in misconceptions and practicalities via tinted formulations; could warrant its own entry (melasma management) that links here as the first-line protection.

Rating difficulties.

• beauty_cumulative scored 5. Defensible against the anchor ("transformative long-term aesthetic profile; reverses or prevents an entire trajectory of accumulated visible damage") because UV is the dominant external driver of facial aging (~80% on chronically exposed sites per Flament 2013; Krutmann 2017) and Hughes 2013 demonstrates the trajectory is preventable. No other intervention in the catalogue blocks the dominant input to visible aging this directly. The alternative call was 4, but the anchor's "prevents an entire trajectory" language matches.
• longevity scored 3, not 4. Nambour shows meaningful melanoma and SCC reductions, but absolute mortality contribution at the population level is real-but-bounded — skin cancer is not heart disease or smoking. The 4 anchor ("one of the more impactful interventions in the catalogue") would over-state.
• controversy scored 2, not 3. The FDA absorption findings and the single-RCT melanoma evidence are real debate, but the core benefit consensus is broad — this isn't an active paradigm fight.

Future-link candidates (not yet existing). Polypodium leucotomos, nicotinamide for actinic keratosis prevention, melasma management, UPF clothing, retinoids for photoaging, topical antioxidant serums (vitamin C/E/ferulic), vitamin D supplementation. The out-of-scope section names most of these without linking; wire them when entries exist.

Separate-entry candidates surfaced. Sunscreen in pregnancy and breastfeeding (currently handled in one paragraph of contraindications) could warrant a dedicated entry if reader demand justifies it; the FDA absorption data and the conservative-default reasoning would carry the weight.

Audience and contraindications fields. No closed-vocabulary contraindications tags applied — the babies-under-six-months exclusion is a life-stage rule the closed vocabulary doesn't have a token for; the pregnancy default-to-mineral is a preference, not a contraindication. Audience left unscoped — the entry applies to everyone, with effect size varying by skin type and exposure rather than excluding any group.